Monitoring oxygen therapy usage in COPD patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research focuses on the development of the Respiratory Oxygen Adherence Monitor (ROAM) system, which tracks how patients use oxygen therapy over time. The ROAM module attaches to the oxygen source and provides real-time feedback on usage patterns without needing internet connectivity. By objectively measuring adherence to long-term oxygen therapy (LTOT), the study aims to enhance clinical management for patients with chronic obstructive pulmonary disease (COPD) and improve health outcomes while reducing healthcare costs associated with non-adherence. The study will also target recruitment efforts to ensure diverse representation among participants.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Post-Bronchodilator FEV1/FVC \<.80

* Race demographics of the recruitment area reflect the population of the Charlottesville Metropolitan Statistical Area (MSA).
* Due to underrepresentation in local demographics, special effort (via targeted advertising) will be made to recruit Hispanic participants to better match national percentages.
* Participants with medical history of COPD
* Subjects has to have a prescription for oxygen use via nasal cannula or mask at home
* At baseline of health with no hospitalization/exacerbation within the past 6 weeks
* Use of Continuous oxygen at baseline

Exclusion Criteria:

Post -Bronchodilator FEV1 \< 25%

* Intermittent oxygen use at home
* Inability to understand simple instructions
* No respiratory infections and exacerbation within 6 weeks of study

Where it's running

• University of Virginia
  Charlottesville, Virginia, United States Recruiting

Study contacts

• Principal investigator: Yun M Shim, MD — Division of Pulmonary and Critical Medicine
• Study coordinator: Roselove NUNOO-ASARE, MA
• Email: RNN3B@VIRGINIA.EDU
• Phone: 434-243-6074

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ensa?fentrine to help prevent COPD flare-ups in adults on standard care

  This study tests whether ensifentrine (MK-5884) can help prevent moderate or severe COPD exacerbations compared with placebo in adults already receiving standard COPD treatment.

  Recruiting at 7 sites Phase 3 Merck Sharp & Dohme LLC · Hialeah Gardens, Florida and 6 other locations · NCT07874815

• GSK Investigational Medicine GSK3862995B: two formulations in healthy adults

  This early-phase study tests two formulations of GSK3862995B in healthy adults to see how the body handles the drug and whether it is safe and tolerable.

  Recruiting Phase 1 GlaxoSmithKline · Cambridge · NCT07789899

• GSK5784283 added to standard COPD therapy vs placebo in moderate to very severe COPD

  This study tests whether adding GSK5784283 to current COPD treatment reduces the rate of COPD flare-ups in adults with eosinophilic COPD and a history of exacerbations.

  Recruiting at 7 sites Phase 3 GlaxoSmithKline · Doral, Florida and 6 other locations · NCT07780669

• GSK5784283 added to standard COPD care versus placebo in adults with moderate to very severe COPD

  This study tests whether adding GSK5784283 to a patient’s current COPD treatment helps reduce COPD flare-ups compared with a placebo in adults with eosinophilic COPD and a history of frequent exacerbations.

  Recruiting at 8 sites Phase 3 GlaxoSmithKline · Cape Coral, Florida and 7 other locations · NCT07780656

• Brenipatide for adults with moderate-to-severe COPD

  This study tests different doses of Brenipatide to see if it is safe and effective for adults with moderate-to-severe COPD, compared with placebo.

  Recruiting at 69 sites Phase 2 Eli Lilly and Company · Birmingham, Alabama and 126 other locations · NCT07759245

• Early depemokimab treatment for COPD with type 2 (eosinophilic) inflammation

  This trial will test whether adding depemokimab early to standard care helps adults with moderate-to-severe COPD who have type 2 (eosinophilic) inflammation.

  Recruiting at 121 sites Phase 3 GlaxoSmithKline · Newport Beach, California and 120 other locations · NCT07177339

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.